[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335265-105":59,"doc-detail-335265-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","systemic-therapy-for-non-melanoma-skin-cancers-latest-advances","Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances","","Review of systemic treatment strategies for locally advanced or metastatic non-melanoma skin cancers updates approved and emerging options. Focus includes squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma, highlighting evidence supporting immunotherapy across tumor types. For basal cell carcinoma, hedgehog inhibitors remain first-line but show limited tolerability. The summary also outlines active trials evaluating neoadjuvant and adjuvant anti-PD-1 and anti-PD-L1 approaches, and contrasts improved survival with historical cytotoxic chemotherapy outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/systemic-therapy-for-non-melanoma-skin-cancers-latest-advances/335265/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/systemic-therapy-for-non-melanoma-skin-cancers-latest-advances/335265.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which non-melanoma skin cancers are covered in this review?","Question",{"text":112,"@type":113},"The review focuses on locally advanced or metastatic squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does the review identify as the major recent development in systemic therapy?",{"text":117,"@type":113},"Immunotherapy is emphasized as effective across non-melanoma skin cancer types and has significantly improved survival compared with historical cytotoxic chemotherapy.",{"name":119,"@type":110,"acceptedAnswer":120},"How is basal cell carcinoma systemic therapy discussed?",{"text":121,"@type":113},"Hedgehog inhibitors are described as first-line for basal cell carcinoma but with poor tolerability, while neoadjuvant and adjuvant anti-PD-1/PD-L1 strategies are under clinical investigation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335265,1790139267,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Current Oncology Reports (2024) 26:1120–1133 [https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1912-024-01570-1  \nSystemic Therapy for Non‑Melanoma Skin Cancers: Latest Advances  \nSpencer Lessans1 · Katie A. O’Connell2 · Jennifer Choe3  \nAccepted: 11 June 2024 / Published online: 2 July 2024 © The Author(s) 2024  \nAbstract  \nPurpose of Review This review provides an update on approved and emerging systemic therapies in the treatment of locally advanced or metastatic non-melanoma skin cancers (squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma) . Recent Findings Many studies demonstrate the effectiveness of immunotherapy for all types of non-melanoma skin cancer. For basal cell carcinoma (BCC), hedgehog inhibitors (HHI) remain first-line but with poor tolerability. Numerous clinical trials studying both neoadjuvant and adjuvant use of anti-PD-1 and anti-PD-L1 therapies in advanced NMSC are under investigation.  \nSummary There is a growing number of systemic therapies available to treat non-melanoma skin cancers. The advent of immunotherapy has revolutionized the field and greatly improved survival compared to historical survival rates with cytotoxic chemotherapy.  \nKeywords Squamous cell carcinoma · Basal cell carcinoma · Merkel cell carcinoma · Immunotherapy · Neoadjuvant  \nIntroduction  \nNon-melanoma skin cancer (NMSC) is a term used to describe a broad range of skin malignancies. It most commonly includes keratinocyte carcinomas: cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC), but also includes Merkel cell carcinomas (MCC) . There are approximately 5.4 million cases of NMSC each year, 80% of which occur in people aged 60 years or older [1, 2]. NMSC is the most common cancer type by incidence and, while it has a low mortality rate, the total number of mortalities is close to that of melanoma due to its high prevalence [3] . The incidence of both BCC and SCC have steadily increased [4]. This is thought to be due, at least in part, to  \nSpencer Lessans and Katie A. O’Connell are the co-first authors.  \n* Jennifer Choe [jennifer.choe@vumc.org](jennifer.choe@vumc.org)  \n1 Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA  \n2 Department of Dermatology, Vanderbilt University Medical Center, Nashville, TN, USA  \n3 Department of Hematology/Oncology, Vanderbilt University Medical Center, Preston Research Building 790, 2220 Pierce Ave, Nashville, TN 37232, USA  \nthe cumulative exposure to ultraviolet (UV) radiation, which is associated with 90% of NMSC cases [5] .  \nSurgical resection utilizing peripheral and deep margin assessment (PDEMA) which includes Mohs surgery and surgical excision using standard vertical sectioning remain the mainstay of treatment for the majority of cases amenable to resection [6] . For cases not amenable to surgical resection, cytotoxic chemotherapy had historically been utilized. Studies looking at outcomes for patients with advanced or metastatic BCC or CSSC were limited to case series, small sample sizes, and lack of randomization, but had limited convincing efficacy prior to the advent or targeted molecular therapies and immunotherapy [7] . In 2011, the first checkpoint inhibitor, ipilimumab, was approved for use in metastatic melanoma followed by approval of pembrolizumab [8] . Since then, immunotherapy has revolutionized cancer therapy, expanding not only into other non-melanoma skin cancers but across solid tumors. The growth of immunotherapy and targeted molecular therapy in treatment of locally advanced and metastatic NMSC has significantly changed treatment options currently available to patients and therefore survival in this population. This review summarizes systemic therapies currently available for treatment of locally advanced and metastatic non-melanoma skin cancers and highlights emerging therapies under investigation.  \nCutaneous Squamous Cell Carcinoma  \nCSCC is the second most common skin cancer behi","cbCaijfWxq7t29YI","https://ap.wps.com/l/cbCaijfWxq7t29YI","pdf",674113,14,"English","# Abstract\n## Purpose of Review\n## Recent Findings\n## Summary\n# Introduction\n## Epidemiology and Risk Factors\n## Current Standard Treatments\n# Cutaneous Squamous Cell Carcinoma\n## Genetic and Tumor Characteristics\n## Advanced CSCC Treatment Options\n# Chemotherapy and Targeted Therapy","[{\"question\":\"Which non-melanoma skin cancers are covered in this review?\",\"answer\":\"The review focuses on locally advanced or metastatic squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma.\"},{\"question\":\"What does the review identify as the major recent development in systemic therapy?\",\"answer\":\"Immunotherapy is emphasized as effective across non-melanoma skin cancer types and has significantly improved survival compared with historical cytotoxic chemotherapy.\"},{\"question\":\"How is basal cell carcinoma systemic therapy discussed?\",\"answer\":\"Hedgehog inhibitors are described as first-line for basal cell carcinoma but with poor tolerability, while neoadjuvant and adjuvant anti-PD-1/PD-L1 strategies are under clinical investigation.\"}]","Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances | PDF",1790010339,35]